Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Fabry Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Alpha Galactosidase A/GLA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Alpha Galactosidase A/GLA Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View Alpha Galactosidase A Products |
| Gene Delivery | Alpha Galactosidase A/GLA Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View Alpha Galactosidase A Products |
| Benchmark Ab | Anti-GLA Antibody Recombinant positive control for ADA/PK assays. |
View Alpha Galactosidase A Products |
| Validator | Alpha Galactosidase A/GLA siRNA Set For knockdown verification in in-vitro models. |
View Alpha Galactosidase A Products |
| Related Target A | IGF2R (Mannose-6-Phosphate Receptor) Critical cellular receptor for lysosomal uptake of exogenous ERT. |
View IGF2R Products |
| Related Target B | NAGA (Alpha-N-acetylgalactosaminidase) Structurally related lysosomal enzyme for selectivity and counter-screening. |
View NAGA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cellular Uptake & Glycosylation Profiling | HEK293 Expressed (Native Glycosylation) ensuring proper Mannose-6-Phosphate (M6P) modifications crucial for receptor binding. |
| Enzymatic Activity & Stability Screening | High Purity (>95%) by SDS-PAGE, Theoretical MW verified, Endotoxin Controlled (<1EU/ug) to prevent assay artifacts. |
| Lack of Immunogenicity Assay Controls | Sequence Verified recombinant benchmark antibodies available for Anti-Drug Antibody (ADA) bridging assays. |
| False Positives in Biomarker Panels | Validated siRNA included for strict specificity checks in Fabry disease cellular models. |
Live Alpha Galactosidase A/GLA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Alpha Galactosidase A (GLA) therapeutics is intensifying, with major players shifting focus from traditional Enzyme Replacement Therapy (ERT) to Next-Generation Prolonged-Half-Life ERTs, mRNA vectors, and Gene Therapy. As first-generation therapies reach the clinic and establish the standard of care for Fabry disease, the next wave of R&D is targeting reduction in immunogenicity, sustained endogenous expression, and improved central nervous system (CNS) or deep tissue penetration.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Next-Gen ERT (PEGylated/Plant-based) | Sanofi, Takeda, Protalix, Chiesi | Fabry Disease | Receptor Binding Assay (Need high-purity HEK293-expressed GLA with M6P) |
| Gene Therapy (AAV/Lentiviral) | Sangamo, 4DMT, Freeline | Fabry Disease (Long-term) | Expression Validation (Need specific benchmark Abs and ELISA reagents) |
| Pharmacological Chaperones | Amicus Therapeutics | Fabry Disease (Amenable Mutations) | Enzyme Stabilization Assay (Need Sequence Verified WT and Mutant Proteins) |
| mRNA / LNP Delivery | Moderna, Translate Bio | Fabry Disease | Translation & Activity Assay (Need Endotoxin Controlled standards) |